Physician profile
Miranda Isom
NPI 1497023865
$17,211.14
in general payments reported to CMS, 2019-2025
32 companies · $3,444 in 2025
The $3,444 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,892 · 2022: $3,418 · 2023: $3,613 · 2024: $3,844 · 2025: $3,444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,900.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $4,395.67 | 2021-2025 | Enbrel, Otezla, Krystexxa |
| Abbvie INC. | $3,929.15 | 2021-2025 | |
| Ucb, INC. | $1,796.26 | 2021-2025 | Cimzia, Bimzelx |
| Pfizer INC. | $1,180.15 | 2021-2025 | |
| Lilly USA, LLC | $1,035.48 | 2021-2025 | Taltz, Zepbound |
| Novartis Pharmaceuticals Corporation | $733.61 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $555.34 | 2021-2025 | Saphnelo |
| Janssen Biotech, INC. | $486.33 | 2021-2025 | Tremfya |
| Glaxosmithkline, LLC. | $375.57 | 2021-2025 | Benlysta |
| Mallinckrodt Hospital Products INC. | $282.47 | 2021-2025 | Acthar |
| Alexion Pharmaceuticals, INC. | $247.68 | 2021-2025 | Strensiq |
| E.R. Squibb & Sons, L.L.C. | $244.30 | 2021-2025 | Orencia |
| Genzyme Corporation | $227.75 | 2021-2025 | |
| Organon LLC | $209.54 | 2022-2025 | Hadlima, Renflexis |
| Radius Health, INC. | $200.22 | 2021-2025 | Tymlos |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $197.81 | 2021-2025 | Lupkynis |
| Actelion Pharmaceuticals US, INC. | $196.75 | 2023-2025 | Uptravi, Opsumit, Opsynvi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $186.37 | 2023-2024 | Cyltezo, Ofev |
| Genentech USA, INC. | $168.77 | 2021-2025 | Actemra |
| Fresenius Kabi USA, LLC | $134.45 | 2023-2025 | Tyenne, Idacio |
| Ferring Pharmaceuticals INC. | $99.65 | 2021-2025 | Euflexxa |
| Horizon Therapeutics Plc | $94.72 | 2021-2023 | Krystexxa |
| Tersera Therapeutics LLC | $39.46 | 2024 | Quzyttir |
| Teva Pharmaceuticals USA, INC. | $31.85 | 2023 | Truxima |
| Fidia Pharma USA INC. | $29.16 | 2024 | Hymovis |
| Ani Pharmaceuticals, INC. | $22.91 | 2022 | |
| Pacira Therapeutics, INC. | $21.33 | 2021 | |
| Janssen Pharmaceuticals, INC | $20.42 | 2021 | |
| Depuy Synthes Sales INC. | $18.47 | 2023 | Monovisc, Orthovisc |
| Sandoz INC. | $18.20 | 2024 | Hyrimoz |
| Kiniksa Pharmaceuticals, LTD. | $16.47 | 2021 | |
| Scilex Pharmaceuticals INC. | $14.83 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Miranda Isom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.